Not Yet RecruitingNot Applicable

Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation

20 participantsStarted 2026-05-01

Plain-language summary

The purpose of this research study is to examine the effects of transcranial Direct Current Stimulation (tDCS) on verbal retrieval and cognition and sensorimotor control and to determine if tDCS can be used as a way to improve retrieval, sensory, and motor abilities in individuals with Parkinson's disease (PD).

Who can participate

Age range50 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with PD having a verbal fluency deficit * 50 - 90 years old * Capable of understanding and signing an informed consent (able to answer consent comprehension questions) * Fluent in speaking and reading English Exclusion Criteria: * A potentially confounding psychological or neurological disorder, including, epilepsy or other seizure disorders; severe traumatic brain injury (based on the Ohio State TBI Identification Method); brain tumor; stroke; present drug abuse/misuse; or Huntington's disease. Participants being seen in the PIs clinics will be assessed for these issues as a part of the standard clinical assessment. * Additionally, exclusion criteria include cranial implants or skull defects that affect tDCS administration; and use of medications that interact with or potentially interact with tDCS effects, including, anti-convulsants, carbamazepine, sulpiride, pergolide, lorazepam, rivastigmine, dextromethorphan, D-cycloserine, flunarizine, ropinirole, or citalopram * Patients with a diagnosis of just dysarthria or who have a deep brain stimulation (DBS) device will be excluded. * Additionally, non-English speakers will be excluded because not all of the screening forms, questionnaires, and tests are available in languages other than English. * Individuals with cognitive impairment, as indicated by a score of 22 or less on the Montreal Cognitive Assessment, will be considered for exclusion due the concern of a reduced ability to consent. P…

What they're measuring

Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency

Timeframe: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment

Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency

Timeframe: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment

Treatment group differences in change from Baseline to 1-week Post-Treatment on COWAT Phonemic Fluency

Timeframe: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment

Treatment group differences in change from Baseline to 2-months Post-Treatment on COWAT Phonemic Fluency

Timeframe: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-months Post-Treatment

Trial details

NCT IDNCT07534397

SponsorThe University of Texas at Dallas

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-10-31

View on ClinicalTrials.gov More PARKINSON DISEASE (Disorder) trials